Syndax Pharmaceuticals SNDX Increase (Decrease) in Inventories

Increase (Decrease) in Inventories at other companies

Jazz PharmaceuticalsJAZZ

$77.8M+119%

BiogenBIIB

——

Gilead SciencesGILD

——

Other financials

Income statement

See full

Revenue$64.9M+224%

Operating income-$34.2M+59.2%

Net income-$42.7M+49.7%

EPS (diluted)-$0.48+51.0%

Balance sheet

See full

Cash & equivalents$130.9M-15.0%

Total debt$350.5M+4.2%

Total equity$41.6M-80.6%

Total assets$472.7M-26.2%

Cash flow

See full

Operating cash flow-$50.3M+47.1%

CapEx$46.8K—

Free cash flow-$80.8M-17.6%

Valuation

See full

Market cap$1.77B+95.0%

Enterprise value$1.99B+84.0%

P/S8.1×-12.6×

Profitability

See full

Operating margin-102.8%-47.8pp

Net margin-111.9%-51.5pp

FCF margin-187.2%-85.4pp

Returns & leverage

See full

Return on equity-189.5%-8,509pp

Debt / equity8.4×+6.9×

Current ratio5.5×-0.3×

Where this comes from

Reported directly by Syndax Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:IncreaseDecreaseInInventories.

The official record: Syndax Pharmaceuticals’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →

Ask your AI about Syndax Pharmaceuticals's increase (decrease) in inventories.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Syndax Pharmaceuticals's increase (decrease) in inventories?: Syndax Pharmaceuticals (SNDX) reported increase (decrease) in inventories of $2.06M in Q1 2026.
How has Syndax Pharmaceuticals's increase (decrease) in inventories changed year-over-year?: Syndax Pharmaceuticals's increase (decrease) in inventories decreased by 50.8% year-over-year, from $4.19M to $2.06M.